You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.
For Australian specific enquiries, please click here.
You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or information contained on the server or site which you will be accessing. The information contained might not comply with the Australian regulatory environment.
Amgen's medicines target diseases that are serious and typically have limited treatment options.
We take advantage of the full potential of biotechnology to collaborate and provide new tools for clinical practice. In Australia, we focus on the following therapeutic areas:
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform the lives of people with cancer.
For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with speed to advance those innovations for the patients who need them.
Cardiovascular disease is a leading global health concern affecting nearly 240 million people worldwide.1 While there are many potential causes of cardiovascular disease, more than 80% of cardiovascular events are preventable.2
Building on more than four decades of experience in developing biotechnology medicines for patients with serious illnesses, Amgen is dedicated to advancing care for and improving the lives of patients with cardiovascular disease. Through research and development, as well as partnerships, Amgen is targeting some of the most significant and complex contributors to cardiovascular disease.
Osteoporosis is a common, chronic disease affecting approximately 500 million people worldwide.3 An osteoporosis-related fracture can have a devastating impact. Approximately 60% of people with osteoporosis do not regain their independence post-fracture, yet these fractures can often be prevented with appropriate treatment.4 At Amgen, we are dedicated to fighting the misconception that osteoporosis must be accepted as a normal part of aging.
Amgen has been an innovator in bone health for over 20 years, discovering, developing, and delivering treatments for osteoporosis. By focusing on molecules that demonstrate improvements across meaningful endpoints, Amgen strives to prevent fractures through optimised treatment and by raising awareness of the treatment care gap and empowering patients to take control of their bone health.
Amgen research targets the root causes of inflammation to develop medicines for autoimmune and chronic inflammatory diseases. We target inflammatory conditions where we see the greatest opportunity for a breakthrough – and where a breakthrough is most needed by patients. Globally we focus on four key areas, based on unmet medical needs and our strongest areas of expertise: dermatology, respiratory, rheumatology, and gastroenterology.
At Amgen, we are committed to advancing science and developing treatments for patients with serious illnesses, including many rare diseases. There are more than 10,000 different rare diseases impacting 400 million people globally. Rare diseases are complex and often underserved. They demand urgent attention and are a core and growing part of Amgen’s mission to serve patients.
Learn more about our products that have reached millions of patients in the fight against serious illnesses.